الفهرس 
Overview Of Bone Marrow Transplantation
Immunology of Bone Marrow TransplantationOnly 14 pages are availabe for public view
 |  | from | 241 |  |  |
| | | from | 241 | | |
Abstract
Allogeneic or autologous BMT has become a standard modality of treatment of a number of diseases. It is considered as a model of iatrogenic immunodeficiency.
Although the immunodeficiency is created under controlled circumstances, the recipients are extremely susceptible to life threatening infections with a variety of bacterial, viral and fungal pathogens especially at the early period postgrafting. In BMT recipients, each of the host mechanisms may become abnormal postgrafting.
Furthermore, during the 1st year after BMT, the functional recovery of the immune system is slow. In particular T-cell immunity seems to be affected and despite almost normal numbers of T-cells from the 3rd month, patient rarely respond to vaccination during the 1st year. A variety of T-cell abnormalities have been described such as
reversion of CD4/CD8 ratio and the expression of cell surface markers that are
usually expressed by minority of T-cell- These abnormalities in T-cell functions
contribute to morbidity and mortality via infectious complications.
In B-ceil postgrafting, there is a rapid expansion based on the CD5+ subset
which are considered both activated and autoimmune reactive cells of B-cell and
could be involved in the pathogenesis of autoimmune disorders detected in early post-
transplant. Also transplant recipients have reduced levels of IgG, FgA and IgM during
the first 6 months after BMT.